Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020111969 - GENE THERAPY DNA VECTOR

Publication Number WO/2020/111969
Publication Date 04.06.2020
International Application No. PCT/RU2019/000801
International Filing Date 11.11.2019
IPC
C12N 15/12 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
C12N 1/21 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/70 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
C12R 1/19 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C-C12Q75
1Microorganisms
01Bacteria or actinomycetales
185Escherichia
19Escherichia coli
CPC
C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Applicants
  • CELL AND GENE THERAPY LTD [GB]/[GB]
  • OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU "PRORYVNYE INNOVATSIONNYE TEKHNOLOGII" [RU]/[RU]
Inventors
  • SAVELIEVA, Natalia
Agents
  • KOVALENKO, Valentina Vasilievna
Priority Data
201814213429.11.2018RU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) GENE THERAPY DNA VECTOR
(FR) VECTEUR D'ADN DE THÉRAPIE GÉNIQUE
Abstract
(EN)
The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. The specified purpose is achieved by using gene therapy DNA vectors are created based on gene therapy DNA vector VTvaflV for the treatment of diseases featuring disruption of blastocyst adhesion, attachment, implantation, and apposition mechanism, female infertility development caused by endometrium failure during the blastocyst implantation period, including during the in vitro fertilization procedures, via the increase of the expression of IL11, LIT, DICER, HOXA10, or WT1 therapeutic genes in humans and animals.
(FR)
La présente invention se rapporte à l’ingénierie génétique et peut être utilisée en biotechnologie, en médecine et en agriculture pour la fabrication de produits de thérapie génique. La présente invention a pour but de fournir des vecteurs d'ADN de thérapie génique qui sont développés sur la base d'un vecteur d'ADN de thérapie génique VTvaflV pour le traitement de maladies telles que celles liées à la perturbation de l'adhésion, la fixation, l'implantation et du mécanisme d'apposition du blastocyste, au développement de l'infertilité féminine provoqué par problème de réceptivité de l'endomètre pendant la période d'implantation de blastocyste, y compris pendant le processus de fécondation in vitro, par l'augmentation de l'expression d'IL11, de LIT, de DICER, de HOXA10, ou de gènes thérapeutiques WT1 chez l'homme et l'animal.
Latest bibliographic data on file with the International Bureau